Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Advanced Solid Tumors 484Solid Tumor 446Advanced Solid Tumor 414Unspecified Adult Solid Tumor, Protocol Specific 362Solid Tumors 336Mesothelioma, Malignant 324Mesothelioma 289Solid Tumor, Adult 124Carcinoma, Non-Small-Cell Lung 122Retinoblastoma 117Lung Neoplasms 77Ovarian Neoplasms 75Melanoma 65Sarcoma 62Carcinoma, Renal Cell 59Stomach Neoplasms 58Pancreatic Neoplasms 58Neoplasms 53Esophageal Neoplasms 53Small Cell Lung Carcinoma 52Colorectal Neoplasms 52Hematopoietic and Lymphatic System Neoplasm 50Uterine Cervical Neoplasms 46Breast Neoplasms 46Solid Tumours 35Neoplasm Metastasis 35Advanced or Metastatic Solid Tumors 35Squamous Cell Carcinoma of Head and Neck 34Carcinoma, Hepatocellular 32Triple Negative Breast Neoplasms 31

Interventions

darolutamide 1Rifampin 1Itraconazole 1Hydroxychloroquine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Refractory or Relapsed Solid Tumors × Other solid neoplasm × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

NCT01634893 2016-03-25

Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors

The University of Texas Health Science Center at San Antonio

Phase 1 Completed
18 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡